Moderna company claimed that it develops the vaccine that combines the booster dose against Covid-19 and the experimental vacine against influenza. The Voice of America reported that, citing the company's statement.
The producer hopes that as time passes, it will be able to add the other vaccines that are now in development (including the one against RS-virus) to Moderna's annual combined inoculation.
"We believe it's a bery big opportunity, if we can take the highly effective annual booster from multiple respiratory diseases at once to the market", said Stephane Bancel, Moderna CEO as he faced the press during the presentation for investors.
The company is holding clinical tests of the vaccine against RS-virus; the test subjects are elderly people.
According to the analysts and investors, Moderna, Pfizer and BioNTech expect to earn billions of dollars from the sale of booster inoculations from Covid-19. The addition of vaccines against flu and other diseasers can increase this profit even more.
The company already has some perspective vaccines against the flu in development. The new vaccine combines the most promising experimental inoculation from influenza and the vaccine against Covid-19.
Earlier, Moderna stated that the third booster dose of the vaccine against coronavirus results in a reliable response of anti-bodies against the Delta strain.